ZHEJIANG JIUZHOU BIOPHARMA CO., LTD.
PharmaZHEJIANG JIUZHOU BIOPHARMA CO., LTD. is a pharmaceutical company with 1 FDA-approved products.
ZHEJIANG JIUZHOU BIOPHARMA CO., LTD.'s Key Drugs
ZHEJIANG JIUZHOU BIOPHARMA CO., LTD.'s core commercial portfolio centers on SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
ZHEJIANG JIUZHOU BIOPHARMA CO., LTD.'s Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG JIUZHOU BIOPHARMA CO., LTD. over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG JIUZHOU BIOPHARMA CO., LTD.'s Therapeutic Areas
Disease areas where ZHEJIANG JIUZHOU BIOPHARMA CO., LTD. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG JIUZHOU BIOPHARMA CO., LTD. Pipeline Snapshot
Active clinical trials for ZHEJIANG JIUZHOU BIOPHARMA CO., LTD. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SITAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 1